Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
arcticnovartis
Tue, 08/12/2025 – 07:19
Read more about Novartis ianalumab Phase III trial meets prim…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
arcticnovartis
Mon, 08/11/2025 – 07:19
Read more about Novartis announces both ianalumab Phase III clinical trials met …
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
arcticnovartis
Thu, 07/17/2025 – 07:07
Read more about Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch reti…
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
arcticnovartis
Thu, 07/17/2025 – 07:04
Read more about Novartis reports strong Q2 with double-digit sales growth and…
Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
arcticnovartis
Thu, 07/17/2025 – 07:04
Read more about Novartis…
Novartis receives approval for first malaria medicine for newborn babies and young infants
arcticnovartis
Tue, 07/08/2025 – 07:19
Read more about Novartis receives approval for first malaria medicine for newborn babies and young infants
…
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
arcticnovartis
Thu, 07/03/2025 – 07:19
Read more about Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
…
Novartis completes acquisition of Regulus Therapeutics
arcticnovartis
Wed, 06/25/2025 – 15:19
Read more about Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has succes…
Novartis completes acquisition of Regulus Therapeutics
arcticnovartis
Wed, 06/25/2025 – 15:19
Read more about Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has succes…
Novartis announces expiration of Regulus Therapeutics tender offer
arcticnovartis
Wed, 06/25/2025 – 07:04
Read more about Novartis announces expiration of Regulus Therapeutics tender offer
Basel, June 25, 2025 – Novartis today anno…
